Search Results - "Norris, Robin E."

Pediatric acute lymphoblastic leukemia presenting with periorbital edema by Stein, Andrew P, Norris, Robin E, Shah, Jay R

“…Abstract Objective To describe a rare presentation of acute lymphoblastic leukemia (ALL) that is important to the field of pediatric otolaryngology. Methods…”
Get full text

Challenges and opportunities in childhood cancer drug development by Norris, Robin E., Adamson, Peter C.

“…Despite recent advances, the acute and long-term morbidity of current curative therapies can be substantial, and several childhood cancers still have…”
Get full text

Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients by LeBlanc, Francis R., Breese, Erin H., Burns, Karen C., Chang, Ellen K., Jones, LaQuita M., Lee, Lynn, Mizukawa, Benjamin, Norris, Robin E., O'Brien, Maureen M., Phillips, Christine L., Perentesis, John P., Rubinstein, Jeremy, Pommert, Lauren

“…Summary Venetoclax (VEN) combined with hypomethylating agents (HMA) decitabine or azacitidine is used for adult acute myeloid leukaemia (AML), but its…”
Get full text

Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors by Norris, Robin E., Adamson, Peter C., Nguyen, Vu T., Fox, Elizabeth

“…Background Poly(ADP‐ribose) polymerase (PARP) signals DNA damage and facilitates DNA repair. PARP inhibitors are being evaluated in cancers with defective DNA…”
Get full text

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment by Gupta, Neeraj, Hanley, Michael J., Venkatakrishnan, Karthik, Perez, Raymond, Norris, Robin E., Nemunaitis, John, Yang, Huyuan, Qian, Mark G., Falchook, Gerald, Labotka, Richard, Fu, Siqing

“…Aim The aim of the present study was to characterize the pharmacokinetics of the oral proteasome inhibitor, ixazomib, in patients with solid tumours and…”
Get full text

Palbociclib in combination with chemotherapy in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia and lymphoma: A Children's Oncology Group study (AINV18P1) by Raetz, Elizabeth A, Teachey, David T, Minard, Charles, Liu, Xiaowei, Norris, Robin E, Denic, Kristina Z, Reid, Joel, Evensen, Nikki A, Gore, Lia, Fox, Elizabeth, Loh, Mignon L, Weigel, Brenda J, Carroll, William L

“…Cyclin D has been shown to play an essential role in acute lymphoblastic leukemia (ALL) initiation and progression, providing rationale for targeting the…”
Get full text

Clinical trials: A plea to cooperative groups, consortia, pharmaceutical companies, and lead investigators for reasonable imaging protocols by Trout, Andrew T., Norris, Robin E., Blank, Peter M. K., Backus, Lori R., Towbin, Alexander J., Nash, Jaylynn M.

Get full text

Barriers to medication adherence among adolescents and young adults with cancer by McGrady, Meghan E., Ketterl, Tyler G., Norris, Robin E., Perentesis, John P., Pettee, Daniel, Mara, Constance A., Breen, Gabriella, Pai, Ahna L. H.

“…Background Adherence promotion is a critical component of adolescent and young adult (AYA) cancer care, but predictors of nonadherence that could be targeted…”
Get full text

Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short‐course EPOCH regimens are safe and effective by Rubinstein, Jeremy D., Shah, Rachana, Breese, Erin H., Burns, Karen C., Mangino, Jennifer L., Norris, Robin E., Lee, Lynn, Mizukawa, Benjamin, O'Brien, Maureen M., Phillips, Christine L., Perentesis, John P., Pommert, Lauren, Absalon, Michael J.

“…No guidelines exist for which intensive chemotherapy regimen is best in pediatric or young adult patients with high‐risk posttransplant lymphoproliferative…”
Get full text

Evaluating the role of phase I expansion cohorts in oncologic drug development by Norris, Robin E., Behtaj, Mohadese, Fu, Pingfu, Dowlati, Afshin

“…Summary Importance Use of expansion cohorts (EC) in phase I trials is increasing. However, the utility of phase I EC in aiding drug development is unclear. We…”
Get full text

Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy by Burke, G. A. Amos, Beishuizen, Auke, Bhojwani, Deepa, Burkhardt, Birgit, Minard-Colin, Véronique, Norris, Robin E., Kabickova, Edita, Pinarli, F. Guclu, Tacyildiz, Nurdan, Howes, Angela, Jong, Jan de, Liu, Grace, Nottage, Kerri, Salman, Mariya, Trixhe, Xavier Woot de, Cairo, Mitchell

Get full text

Adherence and Barriers to Inpatient Physical Therapy Among Adolescents and Young Adults with Hematologic Malignancies by McGrady, Meghan E, Perez, Megan N, Bernstein, Jennifer, Strenk, Mariann, Kiger, Michelle A, Norris, Robin E

“…This study described inpatient physical therapy (PT) adherence and barriers to inpatient PT among adolescents and young adults (AYAs) with hematologic…”
Get more information

Feasibility pilot trial of a tailored medication adherence-promotion intervention for adolescents and young adults with cancer: Study design and protocol by McGrady, Meghan E., Ketterl, Tyler G., Webster, Rachel Tillery, Schwartz, Laura E., Brock, Margaret Y., Szulczewski, Lauren, Burke, Macks, Hommel, Kevin A., Pai, Ahna L.H., Mara, Constance A., Steele, Amii C., Regan, Gillian G., Norris, Robin E.

“…Medication non-adherence is common among adolescents and young adults (AYAs) with cancer and associated with poor health outcomes. AYAs with cancer endorse…”
Get full text

Abstract 2816: Evaluation of Cdk5 inhibitors in neural crest tumors by Norris, Robin E., Pink, John J., Pareek, Tej, Letterio, John L.

“…Abstract Cyclin-dependent kinase 5 (Cdk5) is a ubiquitously expressed proline-directed serine threonine kinase active mainly in post-mitotic neurons due to…”
Get full text

Phase 1 trial of ontuxizumab (MORAb‐004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213) by Norris, Robin E., Fox, Elizabeth, Reid, Joel M., Ralya, Andrew, Liu, Xiaowei W., Minard, Charles, Weigel, Brenda J.

“…Background Ontuxizumab is a humanized IgG monoclonal antibody that targets the cell‐surface glycoprotein endosialin (tumor endothelial marker‐1[TEM‐1]/CD248)…”
Get full text

Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors by Norris, Robin E., Shusterman, Suzanne, Gore, Lia, Muscal, Jodi A., Macy, Margaret E., Fox, Elizabeth, Berkowitz, Noah, Buchbinder, Aby, Bagatell, Rochelle

“…Background EZN‐2208 is a water‐soluble PEGylated conjugate of the topoisomerase inhibitor SN38, the active metabolite of irinotecan. Compared to irinotecan,…”
Get full text

The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL by Rubinstein, Jeremy D., Breese, Erin H., Krupski, M. Christa, O'Brien, Maureen M., Dandoy, Christopher E., Mizukawa, Ben, Khoury, Ruby, Norris, Robin E., Davies, Stella M., Phillips, Christine L.

“…Bridging therapy (BT) given during the period between T-cell collection and initiation of lymphodepleting chemotherapy is indicated for most children with…”
Get full text

A liquid chromatography/tandem mass spectrometry method for determination of obatoclax in human plasma by Moorthy, Ganesh S., Norris, Robin E., Adamson, Peter C., Fox, Elizabeth

“…•We describe a HPLC tandem mass spectrometry assay for obatoclax, a BCL-2 inhibitor.•The analytical method showed excellent sensitivity, precision, and…”
Get full text

Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma by Forlenza, Christopher J., Rosenzweig, Jaclyn, Mauguen, Audrey, Buhtoiarov, Ilia, Cuglievan, Branko, Dave, Hema, Deyell, Rebecca J., Flerlage, Jamie E., Franklin, Anna K., Krajewski, Jennifer, Leger, Kasey J., Marks, Lianna J., Norris, Robin E., Pacheco, Martha, Willen, Faye, Yan, Adam Paul, Harker-Murray, Paul D., Giulino-Roth, Lisa

“…•Among 67 children with relapsed/refractory HL treated with ASCT and brentuximab vedotin consolidation, the 3-year PFS was 85%.•Brentuximab vedotin…”
Get full text

Clinical potency of methotrexate, aminopterin, talotrexin and pemetrexed in childhood leukemias by Norris, Robin E, Adamson, Peter C

“…Purpose Renewed interest in antifols for the treatment of childhood cancers has resulted from identification of novel antifols with broad spectrums of…”
Get full text